tbuckley/cabot-search huggingface dataset:
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
Authors: M. Collins, J.M. Michot, F.X. Danlos, C. Mussini, E. Soularue, C. Mateus, D. Loirat, A. Buisson, I. Rosa, O. Lambotte, S. Laghouati, N. Chaput, C. Coutzac, A.L. Voisin, J.C. Soria, A. Marabelle, S. Champiat, C. Robert, F. Carbonnel
Journal: Annals of Oncology (2017)
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Authors: Eric G. Bluemn, Ilsa M. Coleman, Jared M. Lucas, Roger T. Coleman, Susana Hernandez-Lopez, Robin Tharakan, Daniella Bianchi-Frias, Ruth F. Dumpit, Arja Kaipainen, Alexandra N. Corella, Yu Chi Yang, Michael D. Nyquist, Elahe Mostaghel, Andrew C. Hsieh, Xiaotun Zhang, Eva Corey, Lisha G. Brown, Holly M. Nguyen, Kenneth Pienta, Michael Ittmann, Michael Schweizer, Lawrence D. True, David Wise, Paul S. Rennie, Robert L. Vessella, Colm Morrissey, Peter S. Nelson
Journal: Cancer Cell (2017)
Por qué los adultos contraen la difteria
Authors: J Tomaszunas-Blaszczyk, A Galazka
Journal: Eurosurveillance (1997)

Cuando la difteria era una enfermedad frecuente, la mayoria de los afectados eran ninos. Como poco, un 40% de los casos de difteria eran ninos con edad menor a 5 anos, y casi el 70% de los casos eran ninos menores de 15 anos. Este patron clasico de los casos de difteria era visto en muchos paises incluyendo los Estados Unidos de 1908 a 1934 (1), Alemania de 1929 a 1931 (2), e Inglaterra y Gales de 1936 a 1937 (3).
GW28-e1149 Three-dimensional reconstruction analysis of the esophagus, left atrium, and pulmonary veins: Implications for cryoablation of atrial fibrillation
Authors: GuiTang Yang, Wang Zulu, Xiao Junrui, Yang Benqiang, Sun Mingyu, Liang Ming, Ding Jian, Zhang Yuji, Han Yaling, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
Patellar tendon rupture.
Journal: BMJ (1980)

A patellar tendon rupture involves a complete tear of the tendon that runs from the patella's inferior pole to the tibial tubercle. It is typically seen in males in their third or fourth decade of life. It tends to result from an overall weakened tendon placed under high tensile forces. These tendon ruptures are best classified into acute versus chronic tears, depending on the time from rupture. This type of injury requires prompt diagnosis and surgical repair as the patellar tendon is a part of the extensor mechanism. The extensor mechanism of the knee is crucial to the function of the lower extremity, including ambulation. It is solely responsible for extending and straightening the knee and resisting knee flexion – a crucial aspect of standing with a flexed knee and, therefore, ambulation. Without a properly functioning knee extensor mechanism, the patient is severely limited functionally. Surgical intervention depends on the timing and location of the rupture. Acute ruptures are amenable to primary repair, whereas chronic ruptures often require tendon reconstruction.  Anatomy The knee extensor mechanism is composed of the quadriceps muscle, quadriceps tendon, medial and lateral patellar retinaculum, patella, patellar tendon, and tibial tubercle.The quadriceps muscle is composed of four separate muscles with different origins but a common insertion point on the patella through the quadriceps tendon. Quadriceps Muscles with Origins    Rectus femoris – anterior superior iliac spine and superior acetabular rim    Vastus lateralis – greater trochanter and lateral linea aspera    Vastus intermedius – proximal femoral shaft    Vastus medialis – intertrochanteric line and medial linea aspera   The medial and lateral patellar retinaculum are on their respective sides of the patella and are continuous with the vastus fascia to the tibia and the patella. They are minor patellar stabilizers and, if intact, can provide knee extension and straight leg raising despite a patellar or quadriceps tendon rupture.The patella is a sesamoid bone. It functions to increase the moment arm from the knee joint axis, thereby increasing the mechanical advantage and quadriceps pull in extension. The patella begins to engage the trochlea at 20 degrees of flexion and is fully engaged by 40 degrees of flexion. Joint reaction forces in the patellofemoral joint can be up to three times the body weight with stair climbing and seven times the bodyweight with deep bending.The patellar tendon, by definition, is a ligament as it connects bone (patella) to bone (tibial tubercle). The patellar tendon is approximately 30 mm wide by 50 mm long, with a thickness of 5 to 7 mm. The origin on the inferior pole of the patella is juxtaposed on the articular cartilage on the deep side and becomes confluent with the periosteum of the patella anteriorly. The tibial insertion is narrower and invests the entirety of the tibial tubercle, connecting the quadriceps muscles to the lower leg.
Authors’ reply: Geographic resolution of surveillance data and influenza prevention in large countries
Authors: Saverio Caini, Wladimir J Alonso, Clotilde El-Guerche Séblain, François Schellevis, John Paget
Journal: Eurosurveillance (2017)

Preview this article: Authors' reply: Geographic resolution of surveillance data and influenza prevention in large countries, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/22/40/eurosurv-22-40-4-1.gif
Meningite viral em Chipre e em Inglaterra: Verão de 1996
Authors: M E Ramsay, D W Brown, H Appleton, B Megson, A Polynikis, L Papantoniou, A Eleftheriou
Journal: Eurosurveillance (1996)

Iniciou-se em 5 de Julho de 1996 um surto de meningite viral. Em 28 de Agosto tinham sido admitidos no hospital 316 casos, sendo a maioria deles lactentes e criancas; 55 (17%) tinham menos de 1 ano de idade, 117 (37%) tinham entre 1 e 4 anos, 103 (33%) entre 5 e 14 anos, e 41 (13%) entre 15 e 80 anos. Os casos foram notificados principalmente pelo distrito de Limassol (213/316), mas tambem de Nicosia (43), Larnaca (39), Famagusta (13), Paphos (7), e um caso de um distrito nao especificado. A maioria dos casos foram ligeiros e tiveram alta do hospital em poucos dias; nao houve mortes ou complicacoes graves.
Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA
Authors: Rein Verbeke, Ine Lentacker, Laura Wayteck, Karine Breckpot, Mieke Van Bockstal, Benedicte Descamps, Christian Vanhove, Stefaan C. De Smedt, Heleen Dewitte
Journal: Journal of Controlled Release (2017)
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
Authors: Takahiro Ishiguro, Yuji Sano, Shun-ichiro Komatsu, Mika Kamata-Sakurai, Akihisa Kaneko, Yasuko Kinoshita, Hirotake Shiraiwa, Yumiko Azuma, Toshiaki Tsunenari, Yoko Kayukawa, Yukiko Sonobe, Natsuki Ono, Kiyoaki Sakata, Toshihiko Fujii, Yoko Miyazaki, Mizuho Noguchi, Mika Endo, Asako Harada, Werner Frings, Etsuko Fujii, Eitaro Nanba, Atsushi Narita, Akihisa Sakamoto, Tetsuya Wakabayashi, Hiroko Konishi, Hiroaki Segawa, Tomoyuki Igawa, Takashi Tsushima, Hironori Mutoh, Yukari Nishito, Mina Takahashi, Lorraine Stewart, Ehab ElGabry, Yoshiki Kawabe, Masaki Ishigai, Shuichi Chiba, Masahiro Aoki, Kunihiro Hattori, Junichi Nezu
Journal: Science Translational Medicine (2017)

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody (ERY974) is a promising therapeutic agent for solid tumors.
Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
Authors: A. Arance, R. Dummer, P.A. Ascierto, H. Gogas, M. Mandala, G. Liszkay, C. Garbe, D. Schadendorf, I. Krajsová, R. Gutzmer, V. Chiarion Sileni, C. Dutriaux, J.W.B. de Groot, N. Yamazaki, C. Loquai, L.A. de Parseval, M. Pickard, V. Sandor, C. Robert, K.T. Flaherty
Journal: Annals of Oncology (2017)
Development of TP53 signature diagnostic system using multiplex RT-PCR and observational study to confirm the prognostic value of TP53 signature in breast cancer
Authors: S. Takahashi, T. Fukui, T. Nomizu, Y. Kakugawa, T. Ishida, S. Yamaguchi, S. Kato, N. Ohuchi, N. Gondo, C. Ishioka
Journal: Annals of Oncology (2017)
An outbreak of influenza A(H1N1)v in a boarding school in South East England, May-June 2009
Authors: A Smith, S Coles, S Johnson, L Saldana, C Ihekweazu, É O’Moore
Journal: Eurosurveillance (2009)

An outbreak of influenza A(H1N1)v was confirmed in May and June 2009 in a boarding school in South East England involving 102 symptomatic cases with influenza-like illness. Influenza A(H1N1)v infection was laboratory-confirmed by PCR in 62 pupils and one member of staff. Control measures were implemented as soon as a case was confirmed and included school closure, active case finding and treatment as well as post-exposure prophylaxis offered to the entire school population. Had the outbreak had been detected earlier, the school closed earlier and prophylaxis commenced after the initial cases were detected, we may have seen lower levels of transmission.
Fiebre hemorrágica con síndrome renal: análisis de los brotes epidémicos en Bélgica, Francia, Alemania, los Países Bajos y Luxemburgo en 2005
Authors: P Heyman, C Cochez, G Ducoffre, A Mailles, H Zeller, M Abu Sin, J Koch, G van Doornum, M Koopmans, J Mossong, F Schneider
Journal: Eurosurveillance (2007)

El objetivo de este articulo es describir la situacion de la fiebre hemorragica con sindrome renal (FHSR) en 2005 en cinco paises vecinos (Belgica, Francia, Alemania, los Paises Bajos y Luxemburgo) y definir las zonas mas afectadas.
An open-label, multicenter Phase 1b study of radium-223 + paclitaxel in cancer patients with bone metastases
Authors: R. Geva, J. Lopez, S. Danson, H. Joensuu, A. Peer, S.J. Harris, F. Souza, B.A. Ploeger, K.M.C. Pereira, R. Perets
Journal: Annals of Oncology (2017)
Together JUN and DDIT3 (CHOP) control retinal ganglion cell death after axonal injury
Authors: Stephanie B. Syc-Mazurek, Kimberly A. Fernandes, Michael P. Wilson, Peter Shrager, Richard T. Libby
Journal: Molecular Neurodegeneration (2017)

Optic nerve injury is an important pathological component in neurodegenerative diseases such as traumatic optic neuropathies and glaucoma. The molecular signaling pathway(s) critical for retinal ganglion cell (RGC) death after axonal insult, however, is/are not fully defined. RGC death after axonal injury is known to occur by BAX-dependent apoptosis. Two transcription factors JUN (the canonical target of JNK) and DDIT3 (CHOP; a key mediator of the endoplasmic reticulum stress response) are known to be important apoptotic signaling molecules after axonal injury, including in RGCs. However, neither Jun nor Ddit3 deficiency provide complete protection to RGCs after injury. Since Jun and Ddit3 are important apoptotic signaling molecules, we sought to determine if their combined deficiency might provide additive protection to RGCs after axonal injury.To determine if DDIT3 regulated the expression of JUN after an axonal insult, mice deficient for Ddit3 were examined after optic nerve crush (ONC). In order to critically test the importance of these genes in RGC death after axonal injury, RGC survival was assessed at multiple time-points after ONC (14, 35, 60, and 120 days after injury) in Jun, Ddit3, and combined Jun/Ddit3 deficient mice. Finally, to directly assess the role of JUN and DDIT3 in axonal degeneration, compound actions potentials were recorded from Jun, Ddit3, and Jun/Ddit3 deficient mice after ONC.Single and combined deficiency of Jun and Ddit3 did not appear to alter gross retinal morphology. Ddit3 deficiency did not alter expression of JUN after axonal injury. Deletion of both Jun and Ddit3 provided significantly greater long-term protection to RGCs as compared to Jun or Ddit3 deficiency alone. Finally, despite the profound protection to RGC somas provided by the deficiency of Jun plus Ddit3, their combined loss did not lessen axonal degeneration.These results suggest JUN and DDIT3 are independently regulated pro-death signaling molecules in RGCs and together account for the vast majority of apoptotic signaling in RGCs after axonal injury. Thus, JUN and DDIT3 may represent key molecular hubs that integrate upstream signaling events triggered by axonal injury with downstream transcriptional events that ultimately culminate in RGC apoptosis.
Risque résiduel de transmission d’infections virales par transfusion sanguine en Espagne, 1997-2002, et impact du dépistage génomique viral
Authors: M Alvarez do Barrio, R González Díez, J M Hernández Sánchez, S Oyonarte Gómez
Journal: Eurosurveillance (2005)

L’estimation du risque de transmission d’infections virales par transfusion sanguine est essentiel pour evaluer la securite des dons de sang et l’impact des nouveaux tests de depistage. En Espagne, les taux d’incidence de seroconversion et le risque residuel pour le VHB, le VIH et le VHC ont ete calcules chez les donneurs de sang connus, dans 22 centres de transfusion entre 1997 et 1999, et dans sept centres entre 2000 et 2002. Le risque residuel entre 1997 et 1999 a ete estime a 18,67 par million de dons pour le VHB, 2,49 pour le VIH et 10,96 pour le VHC. Pour la periode 2000-2002, le risque residuel par million de dons a ete estime a 9,78 pour le VHB, 2,48 pour le VIH et 3,94 pour le VHC. Entre 1999 et 2003, pres de 3,4 millions de dons ont ete analyses par depistage genomique viral, principalement par pools de 44 dons, dans 12 des 22 centres espagnols de transfusion sanguine participant a l’etude. Huit dons negatifs pour le VHC et positifs pour le ARN-VHC ont ete trouves, soit un gain approximatif de 1/420 000, contre un gain attendu de 1/240 000 d’apres les donnees de 1995-1997. En Espagne, la mise en place du depistage genomique viral a permis de reduire le risque residuel de transmission d’infections virales par transfusion sanguine.
Persistence of ibrutinib-associated hypertension in CLL pts treated in a real-world experience.
Authors: Lisa M. Gashonia, Joseph R. Carver, Rupal O'Quinn, Suparna Clasen, Mitchell E. Hughes, Stephen J. Schuster, Krista Isaac, Kaitlin Kennard, Jakub Svoboda, Catherine Daniel, Donald Edward Tsai, Molly J Fanning, Sunita Nasta, Daniel Jeffrey Landsburg, Chadi Nabhan, Anthony R. Mato
Journal: Journal of Clinical Oncology (2017)

7525 Background: Cardiovascular (CV) complications associated with ibrutinib (Ibr) include hypertension (HTN) and atrial fibrillation (AFIB) (incidence 26% and 9%, OBrien, ASH 2016). Unlike clinical trials, Ibr toxicities are the most common reasons for its discontinuation in clinical practice. The incidence of HTN in pts treated with Ibr outside of clinical trial setting and its impact on outcomes is unknown. Methods: Retrospective, cohort study of Ibr-treated CLL pts to estimate HTN incidence. Baseline CLL characteristics and co-morbidities were recorded. Blood pressure (BP) measurements were recorded prior to Ibr and sequentially following exposure at specific time points. CV meds were reviewed during a 12 mo follow-up period. The association between Ibr exposure and BP was tested. Results: 153 consecutive CLL pts treated with Ibr at a dose of 420 mg/day were identified. Med age was 57 yr (range: 34-87), relapsed CLL (69%), follow-up 14.5 mo. CV pre-Ibr characteristics included: smoking hx (49%), HTN (42%), hyperlipidemia (39%), diabetes (17%), CAD (12%), AFIB (6.8%). Proportion of pts on ≥1 anti-HTN med increased from 44% pre-Ibr (20% ≥ 2) to 57% during Ibr (30% ≥ 2). Med pre-Ibr BP was 127/70 mmHg (range 90-182/48-95mmHg). At 1, 3, 6, 9, 12 mo, med BPs were 137/73, 141/75, 143/76, 140/75, 142/77 (7 mo to peak BP). There was a significant association between Ibr exposure and increased BP (p&lt;.01). New HTN was observed in 40% of pts and 36% HTN pts had BP increased above baseline (med baseline 135/70 vs peak 161/80). Incidence of new AFIB was 8.1%. In UV analyses, predictive clinical factors for HTN were not identified. Pre-Ibr HTN (OR 3.0, p .05), CAD (OR 4.3, p .03), prior AFIB event (OR 10.8, p.001), hyperlipidemia (OR 3.4, p.05) were associated with post-Ibr AFIB. Conclusions: In the largest real-world series focused on BP in Ibr treated pts, we demonstrate a clear association between Ibr and HTN. Nearly 40% of pts developed HTN within 12 mo of Ibr exposure (vs. 26% in clinical trials over 5 yr). Despite aggressive management (multiple agents), Ibr associated HTN was persistent. These data underscore the critical need for monitoring and management strategies for HTN and follow-up data on future CV events.
SemEHR: surfacing semantic data from clinical notes in electronic health records for tailored care, trial recruitment, and clinical research
Authors: Honghan Wu, Giulia Toti, Katherine I Morley, Zina Ibrahim, Amos Folarin, Ismail Kartoglu, Richard Jackson, Asha Agrawal, Clive Stringer, Darren Gale, Genevieve M Gorrell, Angus Roberts, Matthew Broadbent, Robert Stewart, Richard J B Dobson
Journal: The Lancet (2017)
Detection of a chikungunya outbreak in Central Italy, August to September 2017
Authors: Giulietta Venturi, Marco Di Luca, Claudia Fortuna, Maria Elena Remoli, Flavia Riccardo, Francesco Severini, Luciano Toma, Martina Del Manso, Eleonora Benedetti, Maria Grazia Caporali, Antonello Amendola, Cristiano Fiorentini, Claudio De Liberato, Roberto Giammattei, Roberto Romi, Patrizio Pezzotti, Giovanni Rezza, Caterina Rizzo
Journal: Eurosurveillance (2017)

An autochthonous chikungunya outbreak is ongoing near Anzio, a coastal town in the province of Rome. The virus isolated from one patient and mosquitoes lacks the A226V mutation and belongs to an East Central South African strain. As of 20 September, 86 cases are laboratory-confirmed. The outbreak proximity to the capital, its late summer occurrence, and diagnostic delays, are favouring transmission. Vector control, enhanced surveillance and restricted blood donations are being implemented in affected areas.
Targeted NGS profiling identifies genomic alterations associated with high-risk eBC
Authors: T.R. Wilson, A.R. Udyavar, C-W. Chang, J. Giltnane, J.M. Spoerke, J. Aimi, H. Savage, A. Daemen, R. Bourgon, M.R. Lackner
Journal: Annals of Oncology (2017)
Heath related quality of life (HRQOL) assessment for patients with advanced renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitor (TKI) using electronic patient reported outcome (PRO) in daily clinical practice
Authors: G. Mouillet, A. Pozet, J. Fritzsch, I. Es-Saad, S. Paget-Bailly, A. Foubert, D. Berthod, A. Anota, F. Bonnetain, A. Thiery-Vuillemin
Journal: Annals of Oncology (2017)
Correlation between SPARC expression and efficacy of nab-paclitaxel for advanced gastric cancer refractory to fluoropyrimidine: An exploratory analysis of a phase II trial, CCOG1303
Authors: D. Kobayashi, A. Enomoto, Y. Mochizuki, T. Matsui, H. Nakayama, Y. Kawase, K. Ishigure, T. Shikano, K. Torii, Y. Kodera
Journal: Annals of Oncology (2017)
Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States
Authors: Jeffrey R. Curtis, Fenglong Xie, Christian Smith, Kenneth G. Saag, Lang Chen, Timothy Beukelman, Melissa Mannion, Huifeng Yun, Stefan Kertesz
Journal: Arthritis & Rheumatology (2017)

Opioid prescribing recently has come under intense scrutiny. However, longitudinal patterns of prescription opioid receipt in a population-based cohort of patients with chronic pain, such as those with rheumatoid arthritis (RA), have not been well characterized. The aim of this study was to examine both trends over time and variability in individual physician prescribing of short-term and long-term use of opioids.We identified a cohort of RA patients based on 2006-2014 Medicare data and evaluated longitudinal time trends in "regular" use of opioids. A separate analysis conducted in 2014 assessed rheumatologist-specific variability in regular use of opioid prescriptions in patients with RA.We identified 97,859 RA patients meeting the eligibility criteria. The mean age of the patients was 67 years, 80% were female, 82% were white, and 12% were African American. The most commonly used opioids were those that combined acetaminophen with hydrocodone or propoxyphene. Regular opioid prescribing increased slowly but peaked in 2010 before propoxyphene was withdrawn from the market. Following the withdrawal of propoxyphene, receipt of hydrocodone and tramadol increased commensurately, and overall opioid use declined only slightly. Factors associated with regular use of opioids included younger age, female sex, African American race, back pain, fibromyalgia, anxiety, and depression. Variability between US rheumatologists (n = 4,024) in prescribing the regular use of opioids for their RA patients was high; in the average rheumatologist's practice, 40% of RA patients used prescription opioids regularly. In almost half of the patients, at least some opioid prescriptions were written by a rheumatologist, and 14% received opioids that were co-prescribed concurrently by more than 1 physician.In the US, opioid use in older patients with RA peaked in 2010 and is now declining slightly. Withdrawal of propoxyphene from the US market in 2010 had minimal effect on overall opioid use, because use of propoxyphene was replaced by increased use of other opioids.
The Use of alpha Interferon To Augment the Graft-Versus-Leukaemia Effect of 2nd Stem Cell Transplants and Donor Lymphocyte Infusions in High Risk Paediatric Leukaemias.
Authors: Nichola Cooper, Persis Amrolia, Nick Goulden, Kanchan Rao, Paul Veys
Journal: Blood (2007)
Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome
Authors: Elena Goicoechea de Jorge, Agustín Tortajada, Sheila Pinto García, Sara Gastoldi, Héctor Martín Merinero, Jesús García-Fernández, Emilia Arjona, Mercedes Cao, Giuseppe Remuzzi, Marina Noris, Santiago Rodríguez de Córdoba
Journal: Journal of the American Society of Nephrology (2017)

Atypical hemolytic uremic syndrome (aHUS), a rare form of thrombotic microangiopathy caused by complement pathogenic variants, mainly affects the kidney microvasculature. A retrospective genetic analysis in our aHUS cohort ( n =513) using multiple ligation probe amplification uncovered nine unrelated patients carrying a genetic abnormality in the complement factor H related 1 gene ( CFHR1 ) that originates by recurrent gene conversion events between the CFH and CFHR1 genes. The novel CFHR1 mutants encode an FHR-1 protein with two amino acid substitutions, L290S and A296V, converting the FHR-1 C terminus into that of factor H (FH). Next-generation massive-parallel DNA sequencing (NGS) analysis did not detect these genetic abnormalities. In addition to the CFHR1 mutant, six patients carried the previously uncharacterized CFH-411T variant. In functional analyses, the mutant FHR-1 protein strongly competed the binding of FH to cell surfaces, impairing complement regulation, whereas the CFH-411T polymorphism lacked functional consequences. Carriers of the CFHR1 mutation presented with severe aHUS during adulthood; 57% of affected women in this cohort presented during the postpartum period. Analyses in patients and unaffected carriers showed that FH plasma levels determined by the nonmutated chromosome modulate disease penetrance. Crucially, in the activated endothelial (HMEC-1) cell assay, reduced FH plasma levels produced by the nonmutated chromosome correlated inversely with impairment of complement regulation, measured as C5b-9 deposition. Our data advance understanding of the genetic complexities underlying aHUS, illustrate the importance of performing functional analysis, and support the use of complementary assays to disclose genetic abnormalities not revealed by current NGS analysis.
EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy
Authors: U. Vaishampayan, R.B. Montgomery, M.S. Gordon, D.C. Smith, K. Barber, A. de Haas-Amatsaleh, N. Thapar, C. Chandhasin, F. Perabo, K.N. Chi
Journal: Annals of Oncology (2017)